JYQ-164 is a small molecule inhibitor of Parkinson's disease protein 7 ( PARK7 /DJ-1) in humans. JYQ-164 works by covalently and selectively targeting Cys106, a key residue of PARK7 (IC50=21 nM). The high inhibitory effect of JYQ-164 on PARK7 is 5 times more potent than the previously reported inhibitor JYQ-88. JYQ-164 can be used in Parkinson's disease and cancer research.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Parkinson's Disease | Products > Signaling Pathways > Autophagy | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > PINK1/Parkin
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.